Aneuploidy is a characteristic of the majority of human cancers, and recent studies suggest that defects of mitotic checkpoints play a role in carcinogenesis. MAD1L1 is a checkpoint gene, and its dysfunction is associated with chromosomal instability. Rare mutations of this gene have been reported in colon and lung cancers. We examined a total of 44 cell lines (hematopoietic, prostate, osteosarcoma, breast, glioblastoma and lung) and 133 fresh cancer cells (hematopoietic, prostate, breast and glioblastoma) for alterations of MAD1L1 by RT ± PCR ± SSCP and nucleotide sequencing. Eight mutations consisting of missense, nonsense and frameshift mutations were found, together with a number of nucleotide polymorphisms. All the alterations in cell lines were heterozygous. Frequency of mutations was relatively high in prostate cancer (2/7 cell lines and 2/33 tumor specimens). We placed a mutant truncated MAD1L1, found in a lymphoma sample, into HOS, Ht161 and SJSA cell lines and found that it was less inhibitory than wild type MAD1L1 at decreasing cell proliferation. Co-expression experiments showed that the mutant form had a dominant-negative eect. Furthermore, this mutant impaired the mitotic checkpoint as shown by decreased mitotic indices in HOS cells expressing mutant MAD1L1 after culture with the microtubule-disrupting agent, nocodazole. Our results suggest a pathogenic role of MAD1L1 mutations in various types of human cancer. Oncogene (2001) 20, 3301 ± 3305.
Genetic instability in cancers exists in two distinct arenas, the nucleotide and chromosomal level . Chromosomal instability (CIN) is characterized at the cytogenetic level by marked aneuploidy and is observed in many types of tumors (Cahill et al., 1998; Pihan and Doxsey, 1999; Takahashi et al., 1999) . The mitotic checkpoint is usually defective in cancer cells with CIN. Many genes including the MAD (mitotic arrest de®ciency) and BUB (budding uninhibited by benzimidazole) family of genes have been identi®ed in yeast as well as many other organisms, and these code for proteins which play a role in the mitotic checkpoint (Elledge, 1996; Amon, 1999) . However, very little is known of mitotic checkpoint abnormalities in human cancers. The human homologue of the yeast MAD1, known as MAD1-like1 (MAD1L1) was identi®ed by searching for cellular targets of the Tax oncoprotein of human Tlymphotropic virus type-1 (HTLV-1) (Jin et al., 1998) . MAD1L1 was inactivated by the Tax protein, which might explain the multi-lobulated nuclei and aneuploidy, observed in adult T-cell leukemia/lymphoma (ATL) cells (Kamihira et al., 1994; Tsukasaki et al., 1999) . HTLV-1 initiates ATL, but full manifestation of the disease requires chromosomal and nucleotide alterations (Poiesz et al., 1980; Tsukasaki et al., 2000) . Only a few reports concerning alterations of the mitotic checkpoint genes in humans have been published including mutation of the BUB1 and BUBR1 gene in a small fraction of colon cancers, and mutation of the MAD1L1 gene in one out of 49 lung cancers, but not in any of 19 colon cancers (Cahill et al., 1999; Nomoto et al., 1999) . In the present study, we sought to determine if MAD1L1 was involved in the pathogenesis of a variety of human cancers.
Analysed in this study were 44 human cell lines (19  hematopoietic: HL60, NB4, U937, K562, BC1, BC2,  BC3, KS1, Jurkat, Raji, CA46, JD38, JD39, JD176,  EW36, Daudi, ST1, SO4, KK1; six prostate: LNCaP,  PC3, DU145 MDAPC2A, MDAPC2B, LAPC4; ®ve  osteosarcomas: U20S, HOS, Ht161, SAOS, MG63; ®ve  breasts: MCF7, T47D; MDAMB436, MDAMB468,  MDAMB231; ®ve glioblastomas: AJ, DB, SJ, N39,  PH; four lungs: HTB171, HTB172, HTB180, HTB182) and 133 primary tumor samples (47 ATL, 20 B-cell lymphomas, 33 prostate cancers, 21 breast cancers and 12 glioblastomas). The entire coding region of MAD1L1 was ampli®ed by RT ± PCR (Figure 1 ).
MAD1L1 was found to be expressed in each of the tumors, consistent with its function in actively dividing cells (data not shown). After SSCP and sequencing, eight mutations were found: one nonsense, one frameshift and six missense and all of these were located at a conserved codon and caused a profound substitution in an amino acid (Table 1) . For the cell lines, mutations were found in KS1, LNCaP and LAPC4 which were heterozygous having both shifted and wild type bands on the autoradiogram from the SSCP (Figure 1) . Also, many samples had either one of the four previously reported polymorphisms or two new ones (Table 1 ) (Cahill et al., 1999; Nomoto et al., 1999) . Five silent mutations, each in single samples, were also identi®ed.
To determine whether the mutant (mut)-MAD1L1 gene identi®ed in a B-cell lymphoma (diuse large cell type; 96227ML-MAD1L1) ( Table 1) could have functional activity, we cloned the wild type (wt)-MAD1L1 gene, placed it in an expression vector, generated the mutation, veri®ed its nucleotide sequence and con®rmed the expression of the MAD1L1 gene in transfected cells by immunoblotting (data not shown). The ®rst assay determined the eect of the mutation on clonogenic growth ( Figure 2 ). As compared to empty vector, transfection of HOS, Ht161 and SJSA cells with wt-MAD1L1 reduced their colony numbers. Clonogenic growth after transfection with mut-MAD1L1 resulted in signi®cantly (P50.01) more colonies as compared to transfection of the wild type vector in each cell lines (Figure 2a ). To investigate further the eect of wt-and mut-MAD1L1 on cell growth, a titration analysis of Ht161 clonogenic growth was performed using the various vectors. Expression of mut-MAD1L1 rescued in a dose-dependent manner the inhibition of clonal growth mediated by wt-MADL1, suggesting a dominant negative eect of mut-MAD1L1 on wt-MADL1 (Figure 2b ). Wild-type MAD1L1, shown in the last column in the ®rst set of columns, caused about a 95% reduction in colonies, while the mutant MAD1L1 resulted in a 65% reduction. An equal mixture of the two expression vectors produced a 70% inhibition.
To determine the eect of wt-and mut-MAD1L1 at the mitotic checkpoint, we expressed them in HOS cells and evaluated the cell cycle following microtubule disruption using nocodazole ( Figure 3 ). The wild type HOS cells had greater than a 60% mitotic index after nocodazole treatment, consistent with the cells preserving their mitotic checkpoint (data not shown). DNA content was analysed by two color FACS analysis using GFP and PI. Furthermore, regardless of vectors (empty, wt-MAD1L1 or mut-MAD1L1) after transfection, over 70% of these cells accumulated a DNA content of 4C following nocodazole treatment ( Figure  3a ). In contrast, expression of the mut-MAD1L1 signi®cantly decreased the mitotic index of the HOS cells after nocodazole treatment compared to the untreated cells (P50.01) or those transfected with the wt-MAD1L1 expressing vector (P50.05) (Figure 3b ). Because KS1 and BC3 were established independently from the same individual Arvanitakis et al., 1996) and only KS1 has mutation in MAD1L1, we compared the mitotic index after nocodazole treatment between the two cell lines. Both had impaired mitotic checkpoint, however, with no sig- using the F1-R1 primer set. Asterisk indicates the shifted band that represents the MAD1 mutation in KS1. Note that the abnormal mobility shift in KS1 is neither present in BC3 nor in the other two lymphoma samples. Right panel shows representative results using the F4-R4 primer set. Asterisk indicates the MAD1L1 mutation in 4286PC. Arrowheads indicate common polymorphic alleles. Total RNA was prepared with TRIZOL (GIBCO ± BRL, NY, USA) and used for DNA synthesis with random hexamers and MMLV-RT (Promega, WI, USA). The following primers were used to amplify the entire coding region of MAD1L1 (GeneBank accession no. gi 4580766): F1, 5'-GGGACAGTCTCTGTAATCGCG and R1, 5'-TCCACTCGA-GCCCTCTTGTG for codons 1 ± 84; F2, 5'-GGAGAAAATG-CAGATGGAGCTGAGT and R2, 5'-GAGATCCTCCCCTT-CAGTGC for codons 70 ± 167; F3, 5'-CAGGCTGGCGA-GACCATCAA and R3, 5'-GTACCAGCTCAGACTTCATGT-TCT for codons 154 ± 251 F4, 5'-AAGGATCTGGAGCAG-AAGCTG and R4, 5'-GAATCTGGAAAGGTCTTCTGGAG for codons 226 ± 337 and F5, 5'-GAGAGACTGGACCAGAC-CATG and R5, 5'-TGAGCAGCAGGACCCGTTTCT for codons 318 ± 405 F6, 5'-CTGTTGGAGGAGAGGAAGAAGC and R6, 5'-CAGCTCCATCTCCAGCATGTC for codons 380 ± 477 F7, 5'-GCTGGGAGGCCAGAAACAAAGA, and R7, 5'-GTT-CAGGCTCATGTGCAGCAC for codons 463 ± 548 F8, 5'-GGTGACTATGACCAGAGCAGGA and R8, 5'-TGCGGA-ACTCCTGGATCTTGGT for codons 534 ± 630 F9, 5'-CAG-CGGCTCAAGGAGGTTTTC and R9, 5'-ACCTGCAGGT-CAGGCCAAG for codons 616 ± 718. PCR ampli®cation of the cDNA was carried out for 35 cycles of 1 min at 948C, 1 min at 608C, and 2 min at 728C. The last elongation step was extended to 6 min. All PCR was carried out under standard conditions, 1.5 mM MgCl 2 and 1 mM of each primer. SSCP analysis was done using a MDE gel (FMC BioProducts) as previously reported (Gombart et al., 1995) . All positive results using SSCP were repeated for con®rmation. Aberrantly migrating bands were excised from the gel and reampli®ed with primers identical to those used for SSCP. Puri®ed PCR products were sequenced by the ABI PRIZM dye terminator cycle sequencing reaction (Perkin-Elmer, Foster, CA, USA). Nucleotide changes were con®rmed by primers for both 5' and 3' directions. Sequencing of a non-shifted band in each case was used as a negative control. In case of cell lines, mutations were also con®rmed from aliquot of these cell lines from other institutions MAD1 mutation in human cancers K Tsukasaki et al ni®cant dierence in the index between the two (data not shown). The reason for the lack of dierence between the cell lines is unclear but may be related to insucient sensitivity of the assay or some alteration in other mitotic check point genes in BC3.
Our results show that a subset of human prostate and breast cancers, and lymphomas carry mutations of MAD1L1. We functionally analysed one of these mutations and demonstrated for the ®rst time that mutant MAD1L1 has functional signi®cance lending support to the concept that it has a role in the development and/or progression of these cancers. Concerning the genetic alterations of MAD1L1, a previous report found no mutation in 19 colon cancer cell lines with CIN, another study uncovered one missense mutation in 49 lung cancers (Cahill et al., 1999; Nomoto et al., 1999) . We found three mutations in 44 cell lines and ®ve mutations in 133 fresh cancers. We were unable to obtain RNA from non-malignant cells from the individuals with MAD1L1 mutations. Thus, we do not know if the MAD1L1 alterations are germline or localized to the transformed cells. However, the mutation in KS1 is somatic because no mutation was detected in BC3, and both cell lines were established independently from the same individual Arvanitakis et al., 1996) . We can not totally rule out that some of the missense mutations identi®ed in this study are very rare polymorphisms. Notably, however, all missense mutations occurred at conserved codons, and all the changes in amino acids resulted in a profound change in the side chain (Table  1) . Furthermore, Cahill et al. (1999) and Nomoto et al. (1999) examined 68 cancer-and 156 normal-samples for alterations over entire coding region of MAD1L1, and found none of the eight mutations that we detected. This suggests that the changes we identi®ed are somatic mutations and not polymorphisms. This is the ®rst report that the frequency of MAD1L1 mutations is relatively high in prostate cancer (2/7 cell lines, 2/33 fresh samples). The molecular mechanisms underlying the development and progression of prostate cancers are poorly understood (Sciavolino and Abate-Shen, 1998) . Loss of heterozygosity is more frequent than microsatellite instability, suggesting CIN plays a role in this disease (Cunningham et al., 1996) . Whether MAD1L1 mutations are involved in initiation or progression of prostate cancer is unknown. Because mutant MAD1L1 is probably associated with CIN, those cells harboring this mutation would be expected more easily to acquire additional genetic alterations (Jin et al., 1998) .
A study showed that MAD1L1 could be inactivated by the Tax protein; however, Tax is expressed only in about one out of 10 6 ATL cells in vivo (Kinoshita et al., 1989; Jin et al., 1998) . Except for one silent mutation, we found no MAD1L1 alterations in ATL. Recently, a report has been published on mutations in the BUB1 and BUBR1 genes in ATL (Ohshima et al., 2000) . These latter mutations might be possibly associated with CIN in ATL.
The precise function of MAD1L1 in the mitotic spindle checkpoint remains unknown (Amon, 1999) . According to a model, the spindle checkpoint halts cell-cycle progression prior to anaphase. The MAD1, MAD2, BUB1 and BUB3 checkpoint components bind to the unattached kinetochore, potentially forming a protein complex (Amon, 1999) . Association of MAD1 with MAD2 causes hyperphosphorylation of MAD1 in The nucleotide positions refer to the sequence of the MAD1 transcript (GeneBank accession no. gi4580766); the ®rst codon of the ORF was designated +1.
c Amino acid (AA) conservation in vertebrates (human, mouse and frog). For analysis of the mitotic checkpoint, we used HOS cells which preserves its' mitotic checkpoint after treatment with nocodazole. HOS cells were co-transfected with one of the three vectors described above (2 mg) as well as with pEGFP-C (0.5 mg) using Geneporter for 48 h. For the last 20 h, cells were cultured in the presence of nocodazole (200 nM) (Sigma). Cells were ®xed with 70% ethanol, treated with 100 mg/ul RNAase and stained with 1 mg/ul propidium iodide (PI). To determine the mitotic index (percentage of viable cells arrested in mitosis), at least 100 GFP-positive cells were counted for each measurement using¯uorescence microscopy. Flow cytometric analysis was also conducted to evaluate the cell-cycle pro®le of cells harvested after treatment with nocodazole. Cells were stained with 50 mg/ul PI and analysed with the help of two color FACScan and Cellquest 3.1f software (Becton Dickinson, CA, USA) (Jin et al., 1998) . A¯ag epitope was attached to the 5' of the MAD1L1. Mutation constructs were generated in expression vectors by non-PCR-based, site-directed mutagenesis (Transformer Site-Directed Mutagenesis Kit; Clontech, CA, USA) and con®rmed by sequencing of the nucleotides. For clonal antibiotic recovery assays, we transfected 1610 6 HOS, Ht161 and SJSA cells with one of the following three vectors (2 mg): pcDNA3.1-wtMad1L1, pcDNA3.1-mut-MAD1L1 or empty pcDNA3.1 by Geneporter (GTS, CA, USA). After 48 h, cells were trypsinized and diluted 1 : 50 to 1 : 10 and cultured in medium containing G418 (500 mg/ml). Resistant clones were scored after 10 days by ®xing and staining with Wright-Giemsa. Clonal recovery was determined by counting with an inverted microscope after staining. Transfectants were screened for MAD1L1 expression by immunoblotting with anti-FLAG antibody, M5 (Sigma, St. Louis, MO, USA) as described previously (Kawabata et al., 1999) yeast and is critical for checkpoint function (Chen et al., 1999) . The minimum segment of human MAD1L1 for contacting MAD2 and Tax are amino acids 465 ± 584 and 324 ± 498, respectively (Jin et al., 1998) . Interestingly, ®ve out of the eight mutations in this study were within these two segments.
In this study, overexpression of wt-MAD1L1 inhibited cell growth. Co-expression of mut-MAD1L1 with wt-MAD1L1 rescued in a dose-dependent manner the wt-MAD inhibition of clonal growth, suggesting that the mut-MAD1L1 could behave in a dominant negative fashion. All the MAD1L1 mutations in cell lines were heterozygous. The relatively weak intensity of the shifted band in fresh tumor samples compared to the wild-type bands in Figure 1 , as well as a previous report, suggests that either the tumor has retention of the normal allele and/or prominent contamination with normal cells . The ®rst would be reminiscent of the heterozygous mutations reported for another mitotic checkpoint gene, BUB1 (Cahill et al., 1998) . Mutant MAD1L1 also impairs the mitotic checkpoint as shown by decreased mitotic indices after nocodazole treatment of HOS cells overexpressing this mutant. Taken together, mutant MAD1 may contribute to two major phenotypes of many human cancers, i.e., immortalization and chromosomal instability. Further studies are needed to determine whether defects in other genes also contribute to mitotic checkpoint defects and CIN in human cancers. Agents that can activate the cell-cycle checkpoint might be useful as a way to exploit the dierence between normal and malignant cells and improve the results of chemotherapy.
